Adipose tissue-derived stem cell osteogenic induction composition and osteogenic induction method
A technology of stem cells and compositions, applied in the field of osteogenic induction compositions, can solve the problems of limiting the wide application of adipose-derived mesenchymal stem cells, low osteogenic induction rate, adverse reactions of the body, etc., so as to promote the proliferation of osteoblasts, promote Osteogenic differentiation, guaranteeing the effect of application
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0026] An osteogenic induction composition of adipose-derived mesenchymal stem cells, consisting of the following raw materials: DMEM / F12 medium, disodium β-glycerophosphate, lithium iron phosphate, nano-bismuth selenide, paulownin, fibroblast growth factor, recombinant Insulin; in terms of final concentration, the concentration of each component in the medium is: 3 ng / mL of β-glycerophosphate disodium, 1.2 ng / mL of lithium iron phosphate, 3 ng / mL of nano bismuth selenide with an average particle size of 100 nm, Paulownin 4 ng / mL, fibroblast growth factor 8 μg / mL, recombinant insulin 3 μg / mL.
[0027] A method for osteogenic induction of adipose-derived mesenchymal stem cells, comprising the following process: taking the cultured P3 adipose-derived mesenchymal stem cells and adding an osteogenic induction composition with a cell density of 1×10 4 cells / mL, induce differentiation in a 6-well plate, and induce differentiation at 37°C, 5% CO 2 It was carried out in an incubator,...
Embodiment 2
[0029] An osteogenic induction composition of adipose-derived mesenchymal stem cells, consisting of the following raw materials: DMEM / F12 medium, disodium β-glycerophosphate, lithium iron phosphate, nano-bismuth selenide, paulownin, fibroblast growth factor, recombinant Insulin; in terms of final concentration, the concentration of each component in the medium is: β-glycerophosphate disodium 1ng / mL, lithium iron phosphate 0.5ng / mL, and nano-bismuth selenide with an average particle size of 150nm 2.5 ng / mL , Paulownin 3 ng / mL, fibroblast growth factor 5 μg / mL, recombinant insulin 1 μg / mL.
[0030] A method for osteogenic induction of adipose-derived mesenchymal stem cells, comprising the following process: taking cultured P3 adipose-derived mesenchymal stem cells and adding an osteogenic induction composition, the cell density is 3×10 4 cells / mL, induce differentiation in a 6-well plate, and induce differentiation at 37°C, 5% CO 2 It was carried out in an incubator, and the me...
Embodiment 3
[0032] An osteogenic induction composition of adipose-derived mesenchymal stem cells, consisting of the following raw materials: DMEM / F12 medium, disodium β-glycerophosphate, lithium iron phosphate, nano-bismuth selenide, paulownin, fibroblast growth factor, recombinant Insulin: In terms of final concentration, the concentration of each component in the medium is: 5 ng / mL of β-glycerophosphate disodium, 1.8 ng / mL of lithium iron phosphate, and 4.5 ng / mL of nano-bismuth selenide with an average particle size of 200 nm , Paulownin 5 ng / mL, fibroblast growth factor 10 μg / mL, recombinant insulin 5 μg / mL.
[0033] A method for osteogenic induction of adipose-derived mesenchymal stem cells, comprising the following process: taking cultured P3 adipose-derived mesenchymal stem cells and adding an osteogenic induction composition, the cell density is 5×10 4 cells / mL, induce differentiation in a 6-well plate, and induce differentiation at 37°C, 5% CO 2 It was carried out in an incubato...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap